Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals… News and information for Medical Professionals.
Combination treatment can help improve glucose levels in patients with elevated HbA1Cs.
Read More »GLP-1RA as Add-on Therapy to SGLT-2 Inhibitor
Sedentary Behavior During Pregnancy and Neonatal Adiposity
Lifestyle intervention in pregnancy might reduce adverse effects of maternal obesity on neonatal adiposity.
Read More »First Dual SGLT-1/2 Inhibitor For Adults With Type 1 Declined Approval
Sanofi and Lexicon to continue any required studies in effort to move sotagliflozin forward.
Read More »John Buse Part 3, SGLT2 Inhibitors Effects On Amputations And Cardiovascular Disease
In part 3 of this Exclusive Interview, John Buse talks with Diabetes in Control Publisher Steve Freed about the heart complication and amputation risks on the greater population.
Read More »Association Between Use of Sodium Glucose Cotransporter 2 Inhibitors and Serious Adverse Effects
Study findings warrant cautious consideration and discussions about risk vs benefit when considering therapy.
Read More »Novel Use of SGLT-2 Inhibitors for Treatment of Early-Stage Lung Adenocarcinoma
Study assessed association of cancer and sodium glucose transporter 2 expression as well as potential benefit of SGLT-2 treatment.
Read More »Comparison of Cognitive Benefit Between SGLT-2 Inhibitors and Incretins
Which antihyperglycemic agent will provide the greater cognitive benefit in patients who are elderly and have diabetes?
Read More »Canagliflozin in Patients with Diabetes and Kidney Disease
Can canagliflozin affect the progression of kidney disease in patients with type 2 diabetes?
Read More »Javed Butler Part 1, Evolving Landscape Of Diabetes Heart Failure
In part 1 of this Exclusive Interview, Javed Butler talks with Diabetes in Control Publisher Steve Freed about the use of SGLT to lower risk of heart disease.
Read More »Javed Butler Part 4, How Do SGLT2 Inhibitors Impact Heart Failure
In part 4, the conclusion of this Exclusive Interview, Javed Butler talks with Diabetes in Control Publisher Steve Freed about the use of SGLT2 to help prevent heart failure but not as a current treatment method.
Read More »